Tags

Type your tag names separated by a space and hit enter

[Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Psychiatr Pol. 2007 Jul-Aug; 41(4):457-72.PP

Abstract

Compared with the general population, persons with schizophrenia are characterized with an increased prevalence of obesity, type 2 diabetes mellitus, and cardiovascular disease. Weight gain and increased adiposity is associated with decreases in insulin sensitivity, leading to an increased risk of hyperglycaemia and hyperlipidemia. Antipsychotic drugs can increase adiposity and the range of trials suggests that treatment with antipsychotic medications may be associated with an increased risk of acute (ketoacidosis), subacute (weight gain, glucose intolerance, insulin resistance, dyslipidemia), and chronic (diabetes, hypertension, coronary heart disease) metabolic complications. Conclusions regarding the relative effects of various antipsychotic agents on different components of the metabolic syndrome were reviewed, as well as recommendations for monitoring these effects were noted. Selection and management of the antipsychotic agent reflects a balance between optimizing therapeutic effectiveness, modifying diet and exercise, and avoiding excessive weight gain, dyslipidemia, and insulin resistance.

Authors+Show Affiliations

Samodzielna Pracownia Farmakoterapii IPiN w Warszawie.

Pub Type(s)

English Abstract
Journal Article
Review

Language

pol

PubMed ID

18046977

Citation

Rzewuska, Małgorzata. "[Metabolic Risk During Antipsychotic Treatment in Patients With Schizophrenia]." Psychiatria Polska, vol. 41, no. 4, 2007, pp. 457-72.
Rzewuska M. [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. Psychiatr Pol. 2007;41(4):457-72.
Rzewuska, M. (2007). [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. Psychiatria Polska, 41(4), 457-72.
Rzewuska M. [Metabolic Risk During Antipsychotic Treatment in Patients With Schizophrenia]. Psychiatr Pol. 2007 Jul-Aug;41(4):457-72. PubMed PMID: 18046977.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. A1 - Rzewuska,Małgorzata, PY - 2007/12/1/pubmed PY - 2008/1/30/medline PY - 2007/12/1/entrez SP - 457 EP - 72 JF - Psychiatria polska JO - Psychiatr Pol VL - 41 IS - 4 N2 - Compared with the general population, persons with schizophrenia are characterized with an increased prevalence of obesity, type 2 diabetes mellitus, and cardiovascular disease. Weight gain and increased adiposity is associated with decreases in insulin sensitivity, leading to an increased risk of hyperglycaemia and hyperlipidemia. Antipsychotic drugs can increase adiposity and the range of trials suggests that treatment with antipsychotic medications may be associated with an increased risk of acute (ketoacidosis), subacute (weight gain, glucose intolerance, insulin resistance, dyslipidemia), and chronic (diabetes, hypertension, coronary heart disease) metabolic complications. Conclusions regarding the relative effects of various antipsychotic agents on different components of the metabolic syndrome were reviewed, as well as recommendations for monitoring these effects were noted. Selection and management of the antipsychotic agent reflects a balance between optimizing therapeutic effectiveness, modifying diet and exercise, and avoiding excessive weight gain, dyslipidemia, and insulin resistance. SN - 0033-2674 UR - https://www.unboundmedicine.com/medline/citation/18046977/[Metabolic_risk_during_antipsychotic_treatment_in_patients_with_schizophrenia]_ L2 - http://www.diseaseinfosearch.org/result/6442 DB - PRIME DP - Unbound Medicine ER -